{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:01:30Z","timestamp":1784894490083,"version":"3.55.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with coexisting type 2 diabetes mellitus (T2DM) and hypertension (HTN) face a synergistically elevated risk of major adverse cardiovascular events (MACE). Evidence for prediction models developed specifically in established T2DM-HTN comorbidity population remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To methodologically explore and preliminarily evaluate an interpretable machine learning framework for 1-year MACE prediction in hospitalized patients with coexisting T2DM and HTN using routine clinical data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 1,054 hospitalized patients with T2DM and HTN, of whom 249 (23.6%) experienced MACE during 1-year follow-up. The dataset was randomly divided into training (60%), validation (20%), and independent test (20%) cohorts using stratified sampling. LASSO regression was applied for feature selection from 69 clinical variables. Four algorithms, including logistic regression, random forest, support vector machine, and XGBoost, were developed and compared. Model performance was assessed using discrimination, calibration, and clinical utility metrics. SHapley Additive exPlanations (SHAP) were used to interpret the final model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LASSO identified six stable predictors: HbA1c, age, hypertension duration, cystatin C (CysC), T2DM duration, and carotid intima-media thickness (CIMT). Sex was additionally incorporated based on clinical relevance. Multivariable logistic regression showed that HbA1c, age, hypertension duration, T2DM duration, CysC, and CIMT were associated with 1-year MACE risk, whereas sex was not statistically significant. Logistic regression showed the best relative balance between discrimination, calibration, and simplicity on the validation set, although learning curves indicated limited incremental improvement with increasing training sample size. After isotonic regression recalibration, the final logistic regression model achieved an ROC-AUC of 0.828, a PR-AUC of 0.656, and a Brier score of 0.116 on the independent test set. Decision curve analysis indicated potential clinical net benefit. SHAP linked model predictions to glycemic burden, aging, cumulative disease exposure, renal-related risk, and subclinical atherosclerosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An interpretable logistic regression model based on seven routine clinical variables showed relatively good internal performance for predicting 1-year composite MACE risk in hospitalized patients with coexisting T2DM and HTN. CysC provided additional prognostic information beyond its conventional role as a renal filtration marker, although this association should be interpreted as prognostic rather than causal. External validation is required before the model can be considered for clinical decision support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1871693","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:10:18Z","timestamp":1784891418000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An interpretable machine learning model for predicting 1-year major adverse cardiovascular events in patients with type 2 diabetes and hypertension"],"prefix":"10.3389","volume":"13","author":[{"given":"Juan","family":"Lv","sequence":"first","affiliation":[{"name":"The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xirui","family":"Wang","sequence":"additional","affiliation":[{"name":"The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1101627","DOI":"10.3389\/fendo.2023.1101627","article-title":"Global, regional and national burden of endocrine, metabolic, blood and immune disorders 1990-2019: a systematic analysis of the Global Burden of Disease study 2019.","volume":"14","author":"Wu","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1111\/dom.70528","article-title":"Synergistic effects of hypertension and diabetes on cardiovascular risk in elderly: comparative longitudinal analysis of CHARLS and HRS.","volume":"28","author":"Su","year":"2026","journal-title":"Diabetes Obes Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41440-019-0348-x","article-title":"Improving obesity and blood pressure.","volume":"43","author":"Tanaka","year":"2020","journal-title":"Hypertens Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"sfad282","DOI":"10.1093\/ckj\/sfad282","article-title":"Mechanisms and treatment of obesity-related hypertension-Part 1: mechanisms.","volume":"17","author":"Parvanova","year":"2024","journal-title":"Clin Kidney J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/ijms25020804","article-title":"Diabetic vasculopathy: molecular mechanisms and clinical insights.","volume":"25","author":"Jia","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fphar.2020.00148","article-title":"The vascular consequences of metabolic syndrome: rodent models, endothelial dysfunction, and current therapies.","volume":"11","author":"Tran","year":"2020","journal-title":"Front Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/CM9.0000000000003230","article-title":"Oxidative stress in diabetes mellitus and its complications: from pathophysiology to therapeutic strategies.","volume":"138","author":"Chen","year":"2025","journal-title":"Chin Med J (Engl)."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1161\/ATVBAHA.119.313129","article-title":"Mechanisms of arterial stiffening: from mechanotransduction to epigenetics.","volume":"40","author":"Lacolley","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1124\/pharmrev.120.000096","article-title":"Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies.","volume":"73","author":"Xu","year":"2021","journal-title":"Pharmacol Rev."},{"key":"B10","unstructured":"Notice on Printing and Issuing the Medium- and Long-Term Plan for the Prevention and Treatment of Chronic Diseases in Gansu Province (2017\u20132025).\n          \n          2017"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories.","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation."},{"key":"B12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/s0195-668x(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/bmj.39261.471806.55","article-title":"Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.","volume":"335","author":"Hippisley-Cox","year":"2007","journal-title":"BMJ."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1161\/CIRCULATIONAHA.116.022367","article-title":"Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (prediction for ASCVD risk in China).","volume":"134","author":"Yang","year":"2016","journal-title":"Circulation."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s00125-009-1454-0","article-title":"Cardiovascular risk assessment scores for people with diabetes: a systematic review.","volume":"52","author":"Chamnan","year":"2009","journal-title":"Diabetologia."},{"key":"B16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1046\/j.1464-5491.2003.00934.x","article-title":"Prediction of cardiovascular risk in people with diabetes.","volume":"20","author":"Winocour","year":"2003","journal-title":"Diabet Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e47645","DOI":"10.2196\/47645","article-title":"Pitfalls in developing machine learning models for predicting cardiovascular diseases: challenge and solutions.","volume":"26","author":"Cai","year":"2024","journal-title":"J Med Internet Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e77721","DOI":"10.2196\/77721","article-title":"Beyond comparing machine learning and logistic regression in clinical prediction modelling: shifting from model debate to data quality.","volume":"27","author":"Hu","year":"2025","journal-title":"J Med Internet Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0174944","DOI":"10.1371\/journal.pone.0174944","article-title":"Can machine-learning improve cardiovascular risk prediction using routine clinical data?","volume":"12","author":"Weng","year":"2017","journal-title":"PLoS One."},{"key":"B20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1145\/2939672.2939785","article-title":"XGBoost: a scalable tree boosting system.","volume-title":"Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining.","author":"Chen","year":"2016"},{"key":"B21","unstructured":"Ke\n              G\n            \n            \n              Meng\n              Q\n            \n            \n              Finley\n              T\n            \n            \n              Wang\n              T\n            \n            \n              Chen\n              W\n            \n            \n              Ma\n              W\n            \n          \n          LightGBM: A Highly Efficient Gradient Boosting Decision Tree.\n          \n          2017"},{"key":"B22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-019-1426-2","article-title":"Key challenges for delivering clinical impact with artificial intelligence.","volume":"17","author":"Kelly","year":"2019","journal-title":"BMC Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e73374","DOI":"10.2196\/73374","article-title":"Improving explainability and integrability of medical AI to promote health care professional acceptance and use: mixed systematic review.","volume":"27","author":"Liu","year":"2025","journal-title":"J Med Internet Res."},{"key":"B24","volume-title":"A Unified Approach to Interpreting Model Predictions.","author":"Lundberg","year":"2017"},{"key":"B25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41551-018-0304-0","article-title":"Explainable machine-learning predictions for the prevention of hypoxaemia during surgery.","volume":"2","author":"Lundberg","year":"2018","journal-title":"Nat Biomed Eng."},{"key":"B26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review.","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1698109","DOI":"10.3389\/fcvm.2025.1698109","article-title":"CysC as a predictor of left ventricular remodeling and major adverse cardiovascular events in patients with acute myocardial infarction.","volume":"12","author":"An","year":"2025","journal-title":"Front Cardiovasc Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e42190","DOI":"10.2196\/42190","article-title":"Association of uncontrolled hypertension or diabetes mellitus with major adverse cardiovascular events and mortality in South Korea: population-based cohort study.","volume":"9","author":"Oh","year":"2023","journal-title":"JMIR Public Health Surveill."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.3390\/jcm12165218","article-title":"Impact of advanced age on the incidence of major adverse cardiovascular events in patients with type 2 diabetes mellitus and stable coronary artery disease in a real-world setting in Spain.","volume":"12","author":"Gonz\u00e1lez-Juanatey","year":"2023","journal-title":"J Clin Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1007\/s00392-021-01859-2","article-title":"Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome.","volume":"110","author":"Rossello","year":"2021","journal-title":"Clin Res Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1210\/clinem\/dgac642","article-title":"Duration of diabetes, glycemic control, and risk of heart failure among adults with diabetes: a cohort study.","volume":"108","author":"Yang","year":"2023","journal-title":"J Clin Endocrinol Metab."},{"key":"B32","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1161\/CIRCRESAHA.121.318061","article-title":"Arterial stiffness and cardiovascular risk in hypertension.","volume":"128","author":"Boutouyrie","year":"2021","journal-title":"Circ Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"544302","DOI":"10.3389\/fcvm.2020.544302","article-title":"Arterial stiffness and hypertension in the elderly.","volume":"7","author":"Laurent","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/HYPERTENSIONAHA.122.19256","article-title":"Hypertension, arterial stiffness, and diabetes: a prospective cohort study.","volume":"79","author":"Tian","year":"2022","journal-title":"Hypertension."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2666-7568(22)00247-1","article-title":"Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study.","volume":"4","author":"Lopez-Jaramillo","year":"2023","journal-title":"Lancet Healthy Longev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pcad.2022.11.013","article-title":"Updates on obesity and the obesity paradox in cardiovascular diseases.","volume":"78","author":"Tutor","year":"2023","journal-title":"Prog Cardiovasc Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pcad.2024.01.003","article-title":"Update on obesity, the obesity paradox, and obesity management in heart failure.","volume":"82","author":"Alebna","year":"2024","journal-title":"Prog Cardiovasc Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3390\/jcm12031128","article-title":"Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: a 20-year follow-up cohort study of 42,875 US adults.","volume":"12","author":"Xia","year":"2023","journal-title":"J Clin Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/cells13191662","article-title":"Inflammatory trajectory of type 2 diabetes: novel opportunities for early and late treatment.","volume":"13","author":"Pellegrini","year":"2024","journal-title":"Cells."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e062188","DOI":"10.1136\/bmjopen-2022-062188","article-title":"Low-grade inflammation in type 2 diabetes: a cross-sectional study from a Danish diabetes outpatient clinic.","volume":"12","author":"Okdahl","year":"2022","journal-title":"BMJ Open."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1080\/0886022X.2022.2134026","article-title":"Correlation between serum cystatin C level and renal microvascular perfusion assessed by contrast-enhanced ultrasound in patients with diabetic kidney disease.","volume":"44","author":"Zhao","year":"2022","journal-title":"Ren Fail."},{"key":"B42","doi-asserted-by":"publisher","first-page":"102152","DOI":"10.1016\/j.dsx.2021.05.025","article-title":"Urinary cystatin C as a biomarker of early renal dysfunction in type 2 diabetic patients.","volume":"15","author":"Hassan","year":"2021","journal-title":"Diabetes Metab Syndr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1136\/heartjnl-2020-318860","article-title":"Addition of cystatin C predicts cardiovascular death better than creatinine in intensive care.","volume":"108","author":"Helmersson-Karlqvist","year":"2022","journal-title":"Heart."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1210\/clinem\/dgae225","article-title":"Cystatin C is a predictor for long-term, all-cause, and cardiovascular mortality in US adults with metabolic syndrome.","volume":"109","author":"Song","year":"2024","journal-title":"J Clin Endocrinol Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e2238300","DOI":"10.1001\/jamanetworkopen.2022.38300","article-title":"Assessment of cystatin C level for risk stratification in adults with chronic kidney disease.","volume":"5","author":"Lees","year":"2022","journal-title":"JAMA Netw Open."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/ndt\/gfae011","article-title":"Diabetes mellitus: association of cystatin C- versus creatinine-based estimated glomerular filtration rate with mortality and cardiovascular events.","volume":"39","author":"He","year":"2024","journal-title":"Nephrol Dial Transplant."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis.","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e020745","DOI":"10.1161\/JAHA.121.020745","article-title":"Circulating cystatin C is an independent risk marker for cardiovascular outcomes, development of renal impairment, and long-term mortality in patients with stable coronary heart disease: the LIPID study.","volume":"11","author":"West","year":"2022","journal-title":"J Am Heart Assoc."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1093\/eurheartj\/ehab110","article-title":"The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction.","volume":"42","author":"Ceglarek","year":"2021","journal-title":"Eur Heart J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/medicina58020218","article-title":"Serum cystatin C as a biomarker for early diabetic kidney disease and dyslipidemia in young type 1 diabetes patients.","volume":"58","author":"Stankute","year":"2022","journal-title":"Medicina (Kaunas)."},{"key":"B51","doi-asserted-by":"publisher","first-page":"8135","DOI":"10.3390\/ijms25158135","article-title":"CYSTATINC-A monitoring perspective of chronic kidney disease in patients with diabetes.","volume":"25","author":"Visinescu","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3390\/cells10082071","article-title":"Cystatin C deficiency increases LPS-induced sepsis and NLRP3 inflammasome activation in mice.","volume":"10","author":"Biasizzo","year":"2021","journal-title":"Cells."},{"key":"B53","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/diagnostics12040833","article-title":"Elevated serum cystatin C and decreased cathepsin S\/cystatin C ratio are associated with severe peripheral arterial disease and polyvascular involvement.","volume":"12","author":"Nagy","year":"2022","journal-title":"Diagnostics (Basel)."},{"key":"B54","doi-asserted-by":"publisher","first-page":"sfaf181","DOI":"10.1093\/ckj\/sfaf181","article-title":"Asymmetric dimethylarginine and citrulline are risk factors for cardiovascular disease independently of both estimated and measured GFR.","volume":"18","author":"Rinde","year":"2025","journal-title":"Clin Kidney J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"823","DOI":"10.7326\/0003-4819-137-10-200211190-00012","article-title":"Prevention of plaque rupture: a new paradigm of therapy.","volume":"137","author":"Forrester","year":"2002","journal-title":"Ann Intern Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/eji.200838465","article-title":"Signaling events leading to the curative effect of cystatin on experimental visceral leishmaniasis: involvement of ERK1\/2, NF-kappaB and JAK\/STAT pathways.","volume":"39","author":"Kar","year":"2009","journal-title":"Eur J Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.amjcard.2013.02.019","article-title":"Effect of cystatin C levels on angiographic atherosclerosis progression and events among postmenopausal women with angiographically decompensated coronary artery disease (from the Women\u2019s Angiographic Vitamin and Estrogen [WAVE] study).","volume":"111","author":"Patel","year":"2013","journal-title":"Am J Cardiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1161\/CIRCULATIONAHA.108.827972","article-title":"Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease.","volume":"119","author":"Aikawa","year":"2009","journal-title":"Circulation."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e35144","DOI":"10.1371\/journal.pone.0035144","article-title":"Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF \u03b2\/Smad activation and cardiac fibrosis induced by angiotensin II.","volume":"7","author":"Ma","year":"2012","journal-title":"PLoS One."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","article-title":"Hypertension in diabetes: an update of basic mechanisms and clinical disease.","volume":"78","author":"Jia","year":"2021","journal-title":"Hypertension."},{"key":"B61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","article-title":"Diabetic vascular diseases: molecular mechanisms and therapeutic strategies.","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/CIRCRESAHA.123.321752","article-title":"Endothelial cell dysfunction and increased cardiovascular risk in patients with chronic kidney disease.","volume":"132","author":"Baaten","year":"2023","journal-title":"Circ Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"798958","DOI":"10.3389\/fmed.2021.798958","article-title":"Endothelial dysfunction in hypertension: current concepts and clinical implications.","volume":"8","author":"Gallo","year":"2021","journal-title":"Front Med (Lausanne)."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1871693\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:10:20Z","timestamp":1784891420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1871693\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":63,"alternative-id":["10.3389\/fmed.2026.1871693"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1871693","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1871693"}}